Fortis Spyridon, Corazalla Edward O, Jacobs David R, Kim Hyun J
Division of Pulmonary and Critical Care, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Pulmonary Function Test Laboratory, University of Minnesota Medical Center, Minneapolis, Minnesota.
Respir Care. 2016 Sep;61(9):1192-200. doi: 10.4187/respcare.04647. Epub 2016 May 10.
Health-care providers often diagnose and empirically treat COPD without a confirmative pulmonary function test (PFT) or even despite a PFT that is not diagnostic of obstructive lung disease. We hypothesized that a portion of patients continue to carry a persistent empiric COPD diagnosis and receive treatment with bronchodilators and inhaled steroids after a PFT shows no obstruction.
We retrospectively reviewed single PFT sessions with both spirometry and plethysmography in 1,805 subjects. We included subjects who had a normal PFT or a restrictive ventilatory defect. Persistent empiric COPD diagnosis and treatment were defined when subjects with normal PFTs or a restrictive ventilatory defect continued to carry a health-care provider COPD diagnosis or receive treatment with bronchodilators and/or inhaled glucocorticoids, respectively, after a PFT showed no obstruction.
One quarter of subjects with FEV1/FVC ≥ lower limit of the normal range had nonspecific PFT abnormalities. We included 473 subjects with normal PFTs and 382 with a restrictive ventilatory defect (n = 855). Persistent empiric COPD diagnosis (60 of 855, 7% prevalence) was associated with current (odds ratio [OR] = 44.7, P < .001) and former smoking (OR = 17.3, P < .001) and older age (OR = 1.03/y, P = .005). Persistent empiric treatment (208 of 855, 24%) was associated with empiric COPD diagnosis (OR = 24.6, P < .001), female sex (OR = 1.75, P = .002), current (OR = 2.04, P = 0.040) and former smoking (OR = 1.53, P = 0.029), interstitial lung disease (OR = 2.09, P = .001), other respiratory diagnosis (OR = 3.17, P < .001), and obstructive sleep apnea (OR = 1.79, P = .006).
Persistent empiric COPD diagnosis was 7%, but persistent empiric treatment was common.
医疗保健提供者常常在没有确诊性肺功能测试(PFT)的情况下,甚至在PFT未诊断出阻塞性肺病时,就对慢性阻塞性肺疾病(COPD)进行诊断和经验性治疗。我们推测,一部分患者在PFT显示无阻塞后,仍持续被经验性诊断为COPD,并接受支气管扩张剂和吸入性类固醇治疗。
我们回顾性分析了1805名受试者的单次PFT检查结果,包括肺量计和体积描记法。我们纳入了PFT正常或存在限制性通气功能障碍的受试者。当PFT正常或存在限制性通气功能障碍的受试者在PFT显示无阻塞后,仍继续被医疗保健提供者诊断为COPD或分别接受支气管扩张剂和/或吸入性糖皮质激素治疗时,即定义为持续性经验性COPD诊断和治疗。
FEV1/FVC≥正常范围下限的受试者中有四分之一存在非特异性PFT异常。我们纳入了473名PFT正常的受试者和382名存在限制性通气功能障碍的受试者(n = 855)。持续性经验性COPD诊断(855例中的60例,患病率7%)与当前(比值比[OR]=44.7,P<.001)和既往吸烟(OR = 17.3,P<.001)以及年龄较大(OR = 1.03/岁,P = .005)相关。持续性经验性治疗(855例中的208例,24%)与经验性COPD诊断(OR = 24.6,P<.001)、女性(OR = 1.75,P = .002)、当前(OR = 2.04,P = 0.040)和既往吸烟(OR = 1.53,P = 0.029)、间质性肺疾病(OR = 2.09,P = .001)、其他呼吸系统诊断(OR = 3.17,P<.001)以及阻塞性睡眠呼吸暂停(OR = 1.79,P = .006)相关。
持续性经验性COPD诊断率为7%,但持续性经验性治疗很常见。